Rating Change
Piper Sandler reiterated its Overweight rating on CG Oncology, Inc. Common stock (NASDAQ:CGON) on August 07, 2026.
reiterateNASDAQ:CGON
Piper Sandler Reiterates Overweight Rating on CG Oncology, Inc. Common stock (CGON)
Piper Sandler reiterated its Overweight rating on CG Oncology, Inc. Common stock (NASDAQ:CGON) on August 07, 2026.
At publication ·
What changed
CG Oncology, Inc. Common stock (NASDAQ:CGON) · reiterate
- Firm
- Piper Sandler
- Rating
- Overweight to Overweight
- Price at event
- $75.10
- Market capitalization
- $3.1B
At a glance
Key takeaways
- Piper Sandler reiterated an Overweight rating on CG Oncology (CGON) on August 7, 2026, with the stock trading at $75.10 and a market capitalization of $3.1 billion.
Market Context
CG Oncology, Inc. Common stock operates in the Healthcare sector. The stock currently trades at $75.10 with a market capitalization of $3.1B. The stock has gained 197.0% over the past 52 weeks.
Analyst coverage from Piper Sandler provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for CG Oncology, Inc. Common stock.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for CG Oncology, Inc. Common stock
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 07, 2026 | Piper Sandler | Overweight | N/A |
| Aug 07, 2026 | RBC Capital | Outperform | N/A |
| Aug 07, 2026 | Truist Securities | Buy | N/A |
| May 19, 2026 | Wolfe Research | Peer Perform | N/A |
| May 18, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View CGON Stock Page
Frequently Asked Questions
What does the Overweight rating mean for CGON?
A rating of Overweight from Piper Sandler reflects the analyst's outlook on CG Oncology, Inc. Common stock (NASDAQ:CGON). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the CGON forecast page.